CPHI RSI Chart
Last 7 days
3.2%
Last 30 days
-11.1%
Last 90 days
190.9%
Trailing 12 Months
6.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 6.4M | 0 | 0 | 0 |
2023 | 8.5M | 7.9M | 7.8M | 7.0M |
2022 | 8.9M | 8.1M | 8.1M | 8.1M |
2021 | 11.5M | 10.1M | 9.7M | 9.6M |
2020 | 9.8M | 11.0M | 11.0M | 10.9M |
2019 | 11.6M | 11.0M | 11.1M | 10.9M |
2018 | 13.5M | 13.8M | 12.9M | 12.3M |
2017 | 15.4M | 14.7M | 13.9M | 13.2M |
2016 | 18.3M | 17.6M | 16.8M | 16.1M |
2015 | 20.7M | 20.3M | 19.2M | 20.4M |
2014 | 31.7M | 29.8M | 27.2M | 22.1M |
2013 | 46.7M | 40.1M | 36.0M | 32.8M |
2012 | 79.1M | 74.1M | 65.3M | 54.5M |
2011 | 76.1M | 77.8M | 79.5M | 81.2M |
2010 | 0 | 0 | 0 | 74.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 29, 2023 | li zhilin | acquired | 1,925,990 | 0.14 | 13,757,100 | ceo & interim cfo |
Sep 09, 2021 | li zhilin | acquired | 1,179,200 | 0.67 | 1,760,000 | ceo & interim cfo |
Dec 23, 2020 | li zhilin | acquired | - | - | 2,000,000 | ceo and interim cfo |
Which funds bought or sold CPHI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 34,993 | 34,993 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -20,112 | - | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | sold off | -100 | -33,642 | - | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 5,300 | 5,300 | -% |
May 13, 2024 | HRT FINANCIAL LP | sold off | -100 | -2,000 | - | -% |
May 13, 2024 | UBS Group AG | new | - | 2,721 | 2,721 | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -4,150 | - | -% |
May 10, 2024 | JPMORGAN CHASE & CO | sold off | -100 | -7,916 | - | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Unveiling China Pharma Holdings Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to China Pharma Holdings Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 367.4B | 85.6B | 9.55 | 4.29 | ||||
MRK | 333.7B | 61.4B | 144.7 | 5.43 | ||||
AMGN | 171.1B | 29.5B | 45.48 | 5.8 | ||||
PFE | 163.3B | 57.8B | 130.24 | 2.82 | ||||
GILD | 83.5B | 27.4B | 172.26 | 3.04 | ||||
TEVA | 19.0B | 16.0B | -38.41 | 1.19 | ||||
MID-CAP | ||||||||
PRGO | 4.1B | 4.6B | -535.01 | 0.9 | ||||
ALKS | 4.1B | 1.7B | 9.4 | 2.37 | ||||
BHC | 2.6B | 9.0B | -5.71 | 0.29 | ||||
AMPH | 2.1B | 676.2M | 13.42 | 3.07 | ||||
SMALL-CAP | ||||||||
TLRY | 1.6B | 743.2M | -4.53 | 2.15 | ||||
TXMD | 24.2M | 1.3M | -3.27 | 18.6 | ||||
ACRX | 20.6M | 89.6M | -1.45 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 794.9K | 115.7M | 0 | 0.01 |
China Pharma Holdings Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -36.3% | 1,369,839 | 2,149,686 | 1,803,461 | 1,097,862 | 1,960,290 | 2,921,000 | 1,965,931 | 1,613,156 | 1,604,005 | 2,889,368 | 1,978,627 | 2,415,559 | 2,358,371 | 2,931,104 | 2,400,667 | 3,770,723 | 1,763,955 | 3,048,411 | 2,376,844 | 2,569,408 | 2,929,273 |
Cost Of Revenue | -25.5% | 1,659,863 | 2,228,844 | 2,036,651 | 1,244,523 | 1,782,366 | 2,878,318 | 2,103,687 | 1,842,537 | 1,773,466 | 2,587,432 | 2,275,023 | 2,344,559 | 2,085,641 | 2,369,631 | 2,353,471 | 2,620,925 | 1,569,516 | 2,759,064 | 2,004,085 | 2,405,860 | 2,272,743 |
Gross Profit | -266.4% | -290,024 | -79,158 | -233,190 | -146,661 | 177,924 | 42,682 | -137,756 | -229,381 | -169,461 | 301,936 | -296,396 | 71,000 | 272,730 | 561,473 | 47,196 | 1,149,798 | 194,439 | 289,347 | 372,759 | 163,548 | 656,530 |
Operating Expenses | -43.4% | 626,028 | 1,105,333 | 480,352 | 309,647 | 575,403 | 1,211,694 | 550,898 | 550,212 | 742,257 | 950,626 | 466,008 | 823,948 | 969,198 | 1,662,977 | 999,690 | 1,074,813 | 793,719 | 18,964,820 | 1,017,963 | 916,516 | 990,738 |
S&GA Expenses | -58.3% | 108,187 | 259,552 | 206,524 | 169,820 | 144,432 | 364,397 | 259,376 | 266,451 | 179,561 | 536,902 | 134,292 | 445,478 | 378,335 | 507,567 | 654,090 | 727,642 | 326,095 | 754,943 | 613,110 | 505,866 | 478,691 |
R&D Expenses | -78.7% | 31,451 | 147,552 | 45,773 | 23,747 | 23,008 | 27,999 | 88,747 | 15,063 | 54,049 | 54,048 | 21,374 | 53,456 | 190,086 | 261,473 | 37,628 | 30,044 | 48,819 | 53,995 | 39,716 | 66,008 | 69,918 |
EBITDA Margin | -5988.6% | -0.07 | 0.00 | 0.00 | 0.00 | -0.04 | -0.10 | -0.03 | 0.00 | 0.00 | 0.02 | -0.02 | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | -16.1% | 42,155 | 50,252 | 66,240 | 137,663 | 79,445 | 96,175 | 103,976 | 110,041 | 124,427 | 333,441 | 64,903 | 72,392 | 71,265 | 107,945 | 61,067 | 63,144 | 62,003 | 70,094 | 67,590 | 97,254 | 86,780 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 22.4% | -955,892 | -1,232,213 | -777,600 | -593,029 | -475,976 | -1,264,184 | -790,773 | -888,394 | -1,029,490 | -980,719 | -826,669 | -824,761 | -767,327 | -1,209,037 | -1,009,896 | 13,053 | -660,897 | -18,745,256 | -700,954 | -838,103 | -417,731 |
EBT Margin | -26.2% | -0.55 | -0.44 | -0.40 | -0.39 | -0.40 | -0.49 | -0.46 | -0.46 | -0.41 | -0.35 | -0.37 | - | - | - | - | - | - | - | - | - | - |
Net Income | 22.4% | -955,892 | -1,232,213 | -777,600 | -593,029 | -475,976 | -1,264,184 | -790,773 | -888,394 | -1,029,490 | -980,719 | -826,669 | -824,761 | -767,327 | -1,209,037 | -1,009,896 | 13,053 | -660,897 | -18,745,256 | -700,954 | -838,103 | -417,731 |
Net Income Margin | -26.2% | -0.55 | -0.44 | -0.40 | -0.39 | -0.40 | -0.49 | -0.46 | -0.46 | -0.41 | -0.35 | -0.37 | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -11381.9% | -557,890 | 4,945 | 1,034,554 | -189,167 | -1,440,946 | 611,862 | -33,427 | -509,114 | -880,830 | -205,168 | -866,823 | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -1.7% | 16.00 | 16.00 | 15.00 | 16.00 | 17.00 | 18.00 | 16.00 | 18.00 | 21.00 | 23.00 | 18.00 | 20.00 | 20.00 | 21.00 | 21.00 | 23.00 | 22.00 | 22.00 | 40.00 | 43.00 | 45.00 |
Current Assets | -14.6% | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 8.00 | 9.00 | 4.00 | 5.00 | 5.00 | 5.00 | 5.00 | 7.00 | 6.00 | 6.00 | 6.00 | 8.00 | 8.00 |
Cash Equivalents | -41.1% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 4.00 | 5.00 | 0.00 | 2.00 | 1.00 | 1.00 | 0.00 | 2.00 | 0.00 | 1.00 | 1.00 | 2.00 | 1.00 |
Inventory | -1.4% | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 5.00 |
Net PPE | -9.2% | 6.00 | 7.00 | 8.00 | 8.00 | 9.00 | 10.00 | 10.00 | 11.00 | 13.00 | 13.00 | 14.00 | 14.00 | 15.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 17.00 | 18.00 | 19.00 |
Liabilities | -12.4% | 8.00 | 9.00 | 9.00 | 11.00 | 13.00 | 13.00 | 13.00 | 14.00 | 16.00 | 17.00 | 11.00 | 13.00 | 13.00 | 13.00 | 13.00 | 15.00 | 14.00 | 13.00 | 13.00 | 14.00 | 15.00 |
Current Liabilities | -16.0% | 6.00 | 7.00 | 7.00 | 11.00 | 12.00 | 13.00 | 13.00 | 8.00 | 10.00 | 11.00 | 10.00 | 12.00 | 11.00 | 11.00 | 12.00 | 11.00 | 11.00 | 10.00 | 10.00 | 9.00 | 9.00 |
Shareholder's Equity | 11.2% | 8.00 | 7.00 | 6.00 | 4.00 | 5.00 | 4.00 | 3.00 | 4.00 | 5.00 | 6.00 | 7.00 | 7.00 | 7.00 | 8.00 | 8.00 | 8.00 | 8.00 | 9.00 | 27.00 | 29.00 | 31.00 |
Retained Earnings | -2.4% | -40.25 | -39.29 | -38.10 | -37.28 | -36.69 | -36.21 | -34.95 | -34.16 | -33.27 | -32.24 | -31.26 | -30.43 | -29.61 | -28.84 | -27.63 | -26.62 | -26.63 | -25.97 | -7.23 | -6.53 | -5.69 |
Additional Paid-In Capital | 5.1% | 37.00 | 35.00 | 33.00 | 30.00 | 29.00 | 29.00 | 26.00 | 26.00 | 26.00 | 26.00 | 26.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 |
Accumulated Depreciation | 1.9% | 31.00 | 30.00 | - | - | - | 28.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding | 39.4% | 15.00 | 11.00 | 29.00 | 8.00 | 8.00 | 1.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 4.00 | - | - | - | 11.00 | - | - | - | 17.00 | - | - | - | 16.00 | - | - | - | 8.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -2521.3% | -585 | -22.32 | 1,007 | -216 | -1,468 | 585 | 219 | -333 | -879 | -198 | -450 | 676 | -276 | 335 | -224 | 91.00 | -244 | -22.10 | 480 | 387 | -236 |
Cashflow From Investing | 100.0% | - | -4.53 | -67.45 | 5.00 | 56.00 | 27.00 | -252 | -175 | -1.39 | -7.06 | -415 | - | - | 233 | -259 | -492 | -347 | -50.26 | -12.20 | 328* | -73.87 |
Cashflow From Financing | -77.4% | 7.00 | 30.00 | -476 | 934* | 518 | -672 | 28.00 | -850 | -275 | 4,620 | -425 | 548 | -145 | -10.08 | -1,233 | 1,975 | -106 | -4.99 | -1,345 | -110 | -267 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
Revenue | $ 7,011,299 | $ 8,104,092 |
Cost of revenue | 7,292,384 | 8,598,008 |
Gross (loss) profit | (281,085) | (493,916) |
Operating expenses: | ||
Selling expenses | 780,328 | 1,069,785 |
General and administrative expenses | 1,466,084 | 1,893,269 |
Research and development expenses | 240,080 | 185,858 |
Bad debt benefit | (15,757) | (93,851) |
Total operating expenses | 2,470,735 | 3,055,061 |
Loss from operations | (2,751,820) | (3,548,977) |
Other income (expense): | ||
Interest income | 6,602 | 10,755 |
Interest expense | (333,600) | (434,619) |
Net other expense | (326,998) | (423,864) |
Loss before income taxes | (3,078,818) | (3,972,841) |
Income tax expense | ||
Net loss | (3,078,818) | (3,972,841) |
Other comprehensive income (loss) - foreign currency translation adjustment | (121,011) | (990,764) |
Comprehensive loss | $ (3,199,829) | $ (4,963,605) |
Loss per share: | ||
Basic (in Dollars per share) | $ (0.91) | $ (3.78) |
Weighted average shares outstanding (in Shares) | 3,383,573 | 1,051,371 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 1,423,838 | $ 2,029,971 |
Banker’s acceptances | 65,915 | 13,784 |
Trade accounts receivable, less allowance for doubtful accounts of $13,786,074 and $16,739,527, respectively | 504,448 | 421,531 |
Other receivables, less allowance for doubtful accounts of $27,017 and $27,149, respectively | 157,944 | 29,139 |
Advances to suppliers | 2,013 | 444,637 |
Inventory | 3,732,517 | 2,947,787 |
Prepaid expenses | 110,258 | 77,697 |
Total Current Assets | 5,996,933 | 5,964,546 |
Property, plant and equipment, net | 7,100,425 | 9,973,065 |
Operating lease right of use asset | 116,610 | 39,046 |
Intangible assets, net | 3,255,232 | 1,807,486 |
TOTAL ASSETS | 16,469,200 | 17,784,143 |
Current Liabilities: | ||
Trade accounts payable | 966,420 | 667,082 |
Accrued expenses | 298,829 | 404,807 |
Other payables | 2,282,692 | 2,390,063 |
Advances from customers | 90,507 | 520,295 |
Operating lease liability | 77,727 | 40,445 |
Current portion of lines of credit | 1,030,680 | 2,440,915 |
Convertible, redeemable note payable, net of issue discount | 940,000 | 3,800,000 |
Total Current Liabilities | 6,820,664 | 12,739,447 |
Non-current Liabilities: | ||
Operating lease liability, net of current portion | 39,910 | |
Lines of credit, net of current portion | 1,411,891 | |
Deferred tax liability | 742,114 | 754,698 |
Total Liabilities | 9,014,579 | 13,494,145 |
Commitments and Contingencies (Note 9) | ||
Stockholders’ Equity: | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding | ||
Common stock, $0.001 par value; 500,000,000 shares authorized; 10,625,788 shares and 1,498,180 shares issued and outstanding, respectively | 10,625 | 1,498 |
Additional paid-in capital | 35,282,256 | 28,926,931 |
Retained deficit | (39,290,314) | (36,211,496) |
Accumulated other comprehensive income | 11,452,054 | 11,573,065 |
Total Stockholders’ Equity | 7,454,621 | 4,289,998 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 16,469,200 | 17,784,143 |
Related Party | ||
Current Liabilities: | ||
Borrowings from related parties | $ 1,133,809 | $ 2,475,840 |
Ms. Zhilin Li | |
chinapharmaholdings.com | |
Pharmaceuticals | |
234 |